Headquartered in King of Prussia, PA, CSL Behring is a company offering plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. The company also conducts research on plasma and non-plasma therapies. Its products are also used in cardiac surgery, burn treatment, and to prevent hemolytic disease in newborns. Meanwhile, CSL Behring operates one of the world’s largest plasma collection networks, CSL Plasma, with about 270 plasma collection centers globally. The company was founded in 2007, and its current CEO is Paul McKenzie.